The company discontinued developing emugrobart after two studies showed the drug didn’t achieve intended outcomes.
10don MSN
Over the past decade, early-stage drug innovation has shifted toward China, researchers find
Early-stage drug development worldwide has nearly doubled over the past decade and shifted from a U.S.-dominated model to a ...
The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...
OnKure Therapeutics Inc. (Nasdaq: OKUR), a Boulder precision-oncology company that went public in 2024 via a merger with California-based Reneo Pharmaceuticals Inc., expects to raise about $150 ...
The most familiar artificial intelligence (AI) applications include text generation, facial recognition, and autonomous driving. But there are other AI applications that deserve their share of ...
UC Berkeley School of Public Health researchers are collaborating with the FDA and industry to make drug clinical trials ...
Inflation and the Covid-19 pandemic have put pharmaceutical productivity front and center in recent years. Thus, drug companies are under mounting pressure to prove that new treatments are safe and ...
AI is transforming drug discovery, but accurately predicting patient responses remains challenging. Considering the ongoing need to connect drugs with the right patients and rising drug costs, ...
New active ingredients such as antibodies are usually tested individually in laboratory animals. Researchers have now developed a technology that can be used to test around 25 antibodies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results